For the year ending 2025-12-31, STOK had -$43,838K decrease in cash & cash equivalents over the period. $44,915K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -6,885 |
| Depreciation | 1,770 |
| Amortization and accretion of marketable securities | -1,133 |
| Stock-based compensation | 32,238 |
| Impairment of right of use asset | 696 |
| Loss on disposal of property and equipment | -145 |
| Reduction in the carrying amount of right of use assets | 2,408 |
| Accounts receivable | 4,268 |
| Prepaid expenses and other current assets | 545 |
| Accounts payable, accrued liabilities, and operating leases | 21,289 |
| Deferred revenue | -130 |
| Net cash provided by (used in) operating activities | 45,585 |
| Purchases of property and equipment | 670 |
| Purchases of marketable securities | 322,722 |
| Sales of marketable securities | 136,580 |
| Net cash used in investing activities | -186,812 |
| Proceeds from issuance of common stock upon exercise of stock options | 8,603 |
| Proceeds from employee stock purchase plan | 1,002 |
| Proceeds from controlled equity offering sales agreement, net of commissions | 87,784 |
| Net cash provided by financing activities | 97,389 |
| Net decrease in cash, cash equivalents and restricted cash | -43,838 |
| Cash, cash equivalents and restricted cashbeginning of year | 128,779 |
| Cash, cash equivalents and restricted cashend of year | 84,941 |
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)